A strain of Microbacterium paraoxydants and its use in preparing a product for converting glutamate into GABA
By providing microbacterium paraoxidized that can convert glutamate into GABA, the problem of difficulty in producing GABA in the prior art has been solved, the application field of GABA has been broadened, and a sustainable industrial fermentation method has been provided, which has achieved the goal of Improved efficacy in health and environment.
Patent Information
- Application Number
- CN202411105381.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-13
AI Technical Summary
The existing technology is difficult to provide a strain that can effectively convert glutamate into GABA, which limits the production pathways and application fields of GABA.
A microbacterium paraoxydans Tongji is provided, which is capable of converting glutamate into GABA and provides its application in the form of fermentation agents and products, including in pharmaceutical dosage forms.
Broadening the production pathways and applications of GABA, providing a sustainable industrial fermentation method, enhancing the efficacy in mental health and environmental sustainability.
Smart Images

Figure CN118703400B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical fields of microbiology, biochemistry and fermentation engineering, and in particular to a strain of Microbacterium paraoxydants and application thereof in preparing a product for converting glutamic acid into GABA. Background Art
[0002] Gamma-aminobutyric acid (GABA) is an important neurotransmitter that is widely found in animals and plants. It has multiple physiological functions such as regulating the nervous system, reducing anxiety and improving sleep. In the human body, gamma-aminobutyric acid (GABA) is converted from glutamate by glutamate decarboxylase (GAD). Its chemical structure is C4H9NO2, with an amino group (NH2) and a carboxyl group (COOH). The main role of GABA in the nervous system is to inhibit the excitability of nerve cells by binding to GABA receptors. In addition to the body's own synthesis, bacteria can also produce GABA. The application of GABA-producing bacteria in probiotic formulations is expected to enhance their efficacy in mental health and stress management, and improve the therapeutic effect of microbial intervention therapy. The use of GABA-producing bacteria may contribute to environmental sustainability, including applications in bioremediation and soil improvement, improving environmental health by promoting nutrient cycling and enhancing microbial diversity. The use of GABA-producing bacteria for industrial fermentation provides a sustainable way for GABA production. These technologies are of great significance to the pharmaceutical field, especially in the development of treatments for neurological diseases, where the regulatory role of GABA is particularly important.
[0003] Therefore, it is necessary to provide a new strain capable of producing GABA. Summary of the invention
[0004] The present invention aims to provide a strain of Microbacterium paraoxydants and its application in producing GABA, wherein the strain can effectively convert glutamate into GABA.
[0005] In order to achieve the above object, the present invention adopts the following technical solution:
[0006] In a first aspect of the present invention, a strain of Microbacterium paraoxydans is provided. The deposit number of the strain of Microbacterium paraoxydans is CCTCC NO: M 20241490.
[0007] In a second aspect of the present invention, there is provided a use of the Microbacterium paraoxydants in preparing a product for converting glutamate into GABA.
[0008] In a third aspect of the present invention, a fermentation agent is provided, wherein the fermentation agent comprises:
[0009] fermenting the Microbacterium paraoxydense to obtain a fermentation broth;
[0010] Or the fermentation liquid is spray-dried to obtain a dry powder bacterial agent.
[0011] In a fourth aspect of the present invention, a product for converting glutamate into GABA is provided, wherein the product for converting glutamate into GABA comprises the Microbacterium paraoxydans or the fermentation agent.
[0012] Furthermore, the product for converting glutamate into GABA also includes pharmaceutically acceptable excipients.
[0013] The auxiliary materials include auxiliary materials required for preparing oral dosage forms.
[0014] In a fifth aspect of the present invention, a method for converting glutamate into GABA using the Microbacterium paraoxydants is provided, the method comprising:
[0015] Adding the Microbacterium paraoxydense or the fermentation agent into a culture medium containing glutamic acid to obtain GABA by in vitro fermentation;
[0016] Alternatively, GABA is obtained in vivo by oral administration of the Microbacterium paraoxydense or the fermentation bacteria.
[0017] Furthermore, the culture medium containing glutamate is LB culture medium supplemented with 400 mg / L-600 mg / L glutamate.
[0018] Furthermore, the in vitro fermentation culture temperature is 36° C.-38° C., the pH range is 6.5-7.5, and the most suitable inoculation amount is 5%-10%.
[0019] As a specific embodiment, the method of converting glutamate into GABA using the Microbacterium paraoxydants specifically includes:
[0020] The Microbacterium paraoxydense was inoculated into a test tube containing LB liquid medium and cultured overnight at 35°C in a shaking incubator for activation;
[0021] The bacterial solution after overnight culture was centrifuged, the supernatant was discarded, and the solution was resuspended with sterile water. The solution was centrifuged again, the supernatant was discarded, and the solution was resuspended with sterile water. The OD600 of the resuspended bacterial solution was transferred to a triangular shake flask containing LB culture medium containing glutamate and cultured on a shaking table.
[0022] Furthermore, the model of the gas chromatograph-mass spectrometer is G1540N, the chromatographic column used is TraceGOLDTG-5MS chromatographic column 30m×0.25 μm, the gas flow rate: high-purity nitrogen: 1.5 mL / min, hydrogen: 30 ml / min, air: 300 ml / min. The injection port and detector temperature are 280°C; column temperature: initial temperature 50°C maintained for 2 min, increased to 230°C at a rate of 40°C per minute, increased to 320°C at a rate of 20°C per minute and maintained for 20 min; injection volume is 1 μL; detector temperature: 325°C.
[0023] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
[0024] 1. The present invention provides a strain of Microbacterium paraoxydants and its application, wherein a bacterium capable of converting glutamate into GABA is isolated from a fresh fecal sample of a healthy person. The strain is identified as Microbacterium paraoxydants, which can convert glutamate into GABA in a time-dependent manner.
[0025] 2. The Microbacterium paraoxydants provided by the present invention has the ability to produce GABA, which broadens the production pathway and application field of GABA.
[0026] The preservation date of the Microbacterium paraoxygensis of the present invention is July 8, 2024, and the preservation number is CCTCC NO: M20241490. Its classification name is Microbacterium paraoxydans Tongji , The name of the depository is China Center for Type Culture Collection, and its address is Wuhan University, Wuhan, Hubei, China, Postal Code: 430072. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0028] Figure 1 The Microbacterium paraoxydense isolated in Example 1 Tongji (KP Tongji) Pictures;
[0029] Figure 2 This is the phylogenetic tree of the Microbacterium paraoxygenase (named Tongji in the figure);
[0030] Figure 3 The drug sensitivity test of Microbacterium paraoxydants isolated in Example 2;
[0031] Figure 4 This is the detection result of GABA production by the Microbacterium paraoxydants isolated in Example 3. DETAILED DESCRIPTION
[0032] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.
[0033] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.
[0034] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or obtained by existing methods.
[0035] The following will describe in detail a strain of Microbacterium paraoxydans and its application in combination with examples and experimental data.
[0036] Example 1. Isolation, purification and identification of Microbacterium paraoxydants
[0037] (1) Isolation of Microbacterium paraoxygensis
[0038] Based on the assumption that intestinal bacteria can convert glutamate into GABA by degrading glutamate, the inventors mixed 0.5 g of fresh fecal samples from healthy people with selective culture medium (glutamate as the only carbon source). The culture was incubated in the dark at 37°C and 250 rpm on a rotary shaker. The culture medium was changed after three to four days of culture. After five repetitions, the culture suspension was inoculated on blood agar plates to isolate strains, such as Figure 1 shown.
[0039] (2) Identification of Microbacterium paraoxydense
[0040] The isolated strains were inoculated into LB liquid medium containing 600 mg / L glutamate, and cultured in a shaking incubator at 37°C and 200 rpm for 24 h. The bacterial solution was mixed with 30% glycerol at a volume ratio of 1:1 and sent to Qingke Biotechnology for sequence sequencing. The 16S rDNA sequence of the strain obtained by sequencing was subjected to BLAST comparison analysis in the NCBI database, and the strain was subjected to phylogenetic analysis with the model strain using MEGA11 software, and the phylogenetic tree was constructed using the neighbor-joining method, as shown in Figure 2. Figure 2 As shown;
[0041] Combined with physiological and biochemical characteristics, matrix-assisted laser desorption ionization-time of flight mass spectrometry, it was identified as Microbacterium paraoxydense ( Microbacterium paraoxydans ), we named this bacterium Microbacterium paraoxygensis Tongji ( M. paraoxydans Tongji). It was deposited in the China Center for Type Culture Collection (deposit address: Wuhan University, Wuhan, China) on July 8, 2024, and its classification was named Microbacterium paraoxydans , the deposit number is CCTCC M20241490.
[0042] Embodiment 2, M. paraoxydans Tongji drug sensitivity test
[0043] Using the disc diffusion method, MH medium containing blood was used to M. paraoxydans Tongji was used for drug sensitivity test.
[0044] The results are as follows Figure 3 As shown, M. paraoxydans Tongji was resistant to penicillin G, oxacillin, tobramycin, fosfomycin, cefazolin, cefoxitin, rifampicin, and clindamycin, and was sensitive to cefuroxime, levofloxacin, ampicillin, gentamicin, and co-trimoxazole.
[0045] Drug sensitivity test can quickly and effectively detect the sensitivity of pathogens to various antimicrobial drugs and guide the rational use of drugs in clinical practice. M. paraoxydans Tongji has clinical application prospects.
[0046] Embodiment 3, M. paraoxydans Verification of GABA produced in Tongji
[0047] Will M. paraoxydans Tongji was inoculated in LB medium, and 500 mg / L glutamate was added to the LB medium as the GABA group, and no glutamate was added as the control group. The culture bottle was placed on a shaker at 37°C and incubated at 220 rpm, and samples were taken once a day. Finally, the concentration of GABA was detected by LC-MS / MS. The results are as follows Figure 4 shown.
[0048] Depend on Figure 4 It can be seen that the present application M. paraoxydans Tongji converts glutamate into GABA in a time-dependent manner, while the control group without glutamate does not produce GABA. KP Tongji produced GABA at a concentration of 5.1 mg / L in 24 hours. M. paraoxydans The optimum culture temperature of Tongji is 37℃, the optimum pH is 6.5-7.5, and the optimum inoculation amount is 5%-10%.
[0049] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
[0050] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.
[0051] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0052] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A strain of Microbacterium paraoxydants, characterized in that: The classification of the Microbacterium paraoxydense is named Microbacterium paraoxydans, The accession number is CCTCC M 20241490.
2. Use of the Microbacterium paraoxydants as claimed in claim 1 in the preparation of a product for converting glutamate into GABA.
3. A fermentation agent, characterized in that: The fermentation agent comprises: Fermentation of the Microbacterium paraoxydants according to claim 1 to obtain a fermentation broth; Or the fermentation liquid is spray-dried to obtain a dry powder bacterial agent.
4. A product for converting glutamate into GABA, characterized in that The product for converting glutamate into GABA comprises the Microbacterium paraoxydants according to claim 1 or the fermentation agent according to claim 3.
5. A method for converting glutamate into GABA, characterized in that The method comprises: adding the Microbacterium paraoxydants described in claim 1 or the fermentation agent described in claim 3 to a culture medium containing glutamic acid to obtain GABA by in vitro fermentation.
6. The method according to claim 5, characterized in that The temperature of the in vitro fermentation culture is 36°C-38°C.
